( loxetine in SSRI non- andpartial-respo...)In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression,Health

loxetine in SSRI non- and partial-responders: Effects on painful physical symptoms of depression. Presented at the American Psychiatric Association 160th Annual Meeting, San Diego, 23 May 2007
2 Baghai, TC., Moller, HJ, Rupprecht, R. (2006) Recent progress in pharmacological and non-pharmacological treatment options of major depression. Curr Pharm Des. ;12(4):503-15.
3 Ruhe HG, Huyser J, Swinkels JA, Schene AH. (2006) Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry. Dec;67(12):1836-55.
4 Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg A, Stewart JW, et al (2006). Acute and Longer-term Outcomes in Depressed Outpatients Who Required One or Several Treatment Steps: A STAR*D Report. Am J of Psych Oct; 163(11):1905-1917
5 Perahia, DGS, Quail, D, Desaiah D, Rasmussen K. Switching to Duloxetine From Other Antidepressants: A Regional Multicenter Trial Comparing Two Switching Techniques. Presented at the American College of Neuropsychopharmacology45th Annual Meeting, Hollywood, FL December 2006
6 Bymaster, FP et al. “The Dual Transporter Inhibitor Duloxetine: A Review of its Preclinical Pharmacology, Pharmacokinetic Profile, and Clinical Results in Depression.” Current Pharmaceutical Design. 2005; 11: 1475-1493.
7 World Health Organization. Factsheet - Depression, 2005. Available at: http://www.who.int/mental_health/management/depression/definition/en/. Last visited 26 April 2007
8 Murray CJL, Lopez AD, eds. The Global Burden of Disease; 1996.
9 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., Text Revision. Washington DC: American Psychiatric Association; 2000:345-428.
10 Ormel J, et al. Common mental disorders and disability across cultures: results from the WHO Collaborative Study on Psychological Problems in General Health Care. JAMA. 1994;272:1741–1748.<
'"/>




Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. In New Study, Duloxetine Reduced Non-specific Pain and Emotional Symptoms Associated with Depression
2. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
3. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
4. MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
7. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
8. The International Myeloma Foundation Says New Clinical Trial Results Could Improve Survival While Reducing Side Effects For Many Patients
9. New Study Confirms Role for Pertussis Immunization of Entire Family in Reducing Infant Pertussis
10. Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in Their Phase 2 Clinical Trial
11. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo